摘要
门脉高压症（portal hypertension）是各种原因导致门静脉系统压力升高引起的一组临床综合征,其基本病理生理特征是门静脉系统血流受阻和（或）血流量增加,门静脉及其属支血管内静压升高并伴侧支循环形成[1]。
出处
《中国肝脏病杂志（电子版）》
CAS
2012年第1期59-62,共4页
Chinese Journal of Liver Diseases：Electronic Version
参考文献29
-
1欧蔚妮,邢卉春.门静脉高压症的药物治疗现状[J].实用医学杂志,2010,26(7):1087-1089. 被引量：2
-
2Reynaert H,Urbain D,Geerts A. Regulation of sinusoidal perfusion in portal hypertension[J].Anat Rec (Hoboken),2008.693-698.
-
3Reynaert H,Thompson MG,Thomas T. Hepatic stellate cells:role in microcirculation and pathophysiology of portal hypertension[J].Gut,2002.571-581.
-
4Bosch J,Pizcueta P,Feu F. Pathophysiology of portal hypertension[J].Gastroenterology Clinics of North America,1992.1-14.
-
5张影,綦盛麟,张勇.慢性肝病血管新生研究[J].肝脏,2011,16(2):156-158. 被引量：2
-
6Bosch J,Berzigotti A,Garcia-Pagan JC. The management of portal hypertension:rational basis,available treatments and future options[J].Journal of Hepatology,2008,(Suppl 1):S68-S92.
-
7Bosch J,Abraldes JG,Fernandez M. Hepatic endothelial dysfunction and abnormal angiogenesis:new targets in the treatment of portal hypertension[J].Journal of Hepatology,2010.558-567.
-
8O'Reilly MS. Antiangiogenesis and vascular endothelial growth factor/vascular endothelial growth factor receptor targeting as part of a combined-modality approach to the treatment of cancer[J].International Journal of Radiation Oncology,Biology,Physics,2007.S64-S66.
-
9Fernandez M,Vizzutti F,Garcia-Pagan JC. Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice[J].Gastroenterology,2004.886-894.
-
10Fernandez M,Mejias M,Angermayr B. Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats[J].Journal of Hepatology,2005.98-103.
二级参考文献52
-
1顾驾云,章幼奕,邹美银.肝硬化患者VEGF水平和终末期肝病模型评分的临床意义[J].南通大学学报（医学版）,2009,29(4):242-243. 被引量：1
-
2章幼奕,邹美银,吴月平,施旦华,陶虎,高金华.失代偿性肝硬化患者血清VEGF、TGF-β_1、TNF-α检测及临床意义[J].南通大学学报（医学版）,2009,29(4):244-246. 被引量：5
-
3Claudia Paternostro,Ezio David,Erica Novo,Maurizio Parola.Hypoxia,angiogenesis and liver fibrogenesis in the progression of chronic liver diseases[J].World Journal of Gastroenterology,2010,16(3):281-288. 被引量：23
-
4叶春华,刘浔阳.静脉应用血管内皮生长因子治疗肝硬化门静脉高压症大鼠的实验研究[J].中国医学工程,2005,13(3):232-235. 被引量：6
-
5Groszmann R J, Wongcharatrawee S. The hepatic venous pressure gradient: Anything worth doing should be done right [J]. Hepatology, 2004, 39 (2) : 280-283.
-
6Spiegel B M, Targownik L, Dulai G S, et al. Endoscopic screening for esophageal varices in cirrhosis: is it ever cost effective [J]. Hepatology,2003, 37(2) : 366-377.
-
7De Franchis R. Evolving consensus in portal hypertension report of the baveno Ⅳ consensus workshop on methodology of diagnosis and therapy in portal hypertension [J]. J Hepatol,2005,43 (1):167- 176.
-
8Chen W, Nikolova D, Frederiksen S L, et al. 280 Beta-blockers reduce mortality in cirrhotic patients with oesophageal varices who have never bled (cochrane review) [J]. J nepatol,2004, 40(Suppl 1) :67-71.
-
9Garcia-Tsao G, Sanyal A J, Grace, N D, et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis [ J ]. Hepatology, 2007,46 ( 3 ) : 922-938.
-
10Merkel C, Marin R, Sacerdoti D, et al. Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis [J]. Hepatology, 2000,31 (2) : 324-329.
共引文献10
-
1严秀琼.肝硬化门脉高压中彩色B超的诊断价值分析[J].医学信息（医学与计算机应用）,2014,0(16):104-105. 被引量：3
-
2骆玉露,胡晓捷.彩色多普勒超声对老年肝硬化门静脉高压的诊断价值[J].中国老年学杂志,2014,34(9):2397-2399. 被引量：15
-
3蒋伟伟,赵金满,于良立.外源性血管内皮生长因子对肝硬化大鼠肝组织血管的影响[J].世界华人消化杂志,2011,19(10):1009-1014. 被引量：1
-
4蒋伟伟,赵金满,于良立.外源性血管内皮生长因子对肝硬化大鼠门静脉压力的影响[J].中国医科大学学报,2011,40(8):706-708. 被引量：3
-
5于良立,赵金满,蒋伟伟.重组血管内皮生长因子165对大鼠肝纤维化的影响[J].世界华人消化杂志,2011,19(21):2214-2219. 被引量：3
-
6于良立,赵金满,蒋伟伟.重组血管内皮生长因子165对肝硬化大鼠肝功能的影响[J].中国医科大学学报,2011,40(12):1092-1095.
-
7吉其胜,曾孝琼,易小洪.彩色多普勒超声在肝硬化门脉高压中的诊断价值[J].西部医学,2012,24(4):712-713. 被引量：26
-
8倪静.彩色B超在肝硬化门脉高压中的诊断价值研究[J].实用心脑肺血管病杂志,2013,21(8):95-96. 被引量：24
-
9肖辉雪,郑康超,陆建林,吕家高,肖淼淼,杨向俐,许东.非选择性β受体阻滞剂在门静脉高压患者中的应用[J].医学与哲学（B）,2016,37(7):59-61.
-
10张义.门静脉高压对肝细胞癌经动脉化疗栓塞术后疗效的影响[J].中国药物与临床,2021,21(7):1175-1177.
同被引文献8
-
1Shao-Hua Guo, Chong-Hui Li,Yong-Liang Chen, Jian-Ning Song,Ai-Qun Zhang and Cheng Zhou Department of Hepatobiliary Surgery (Guo SH, Li CH, Chen YL, Song JN, Zhang AQ and Zhou C) and Department of Surgical Oncology (Guo SH), General Hospital of PLA, Beijing 100853, China.Effects of partial portal vein arterialization on the hilar bile duct in a rat model[J].Hepatobiliary & Pancreatic Diseases International,2011,10(5):533-538. 被引量：8
-
2李坚,贾英斌,关晓东,蔡潮农,周文英,张百萌.入肝门静脉动脉化对肝部分切除大鼠肝细胞能量代谢的影响[J].消化肿瘤杂志（电子版）,2011,3(1):40-44. 被引量：4
-
3刘琦,李坚,关晓东,郭辉,蔡潮农,张百萌.入肝门静脉动脉化加门腔分流术对肝硬化大鼠血流动力学的影响[J].中华普通外科学文献（电子版）,2010,4(2):16-19. 被引量：10
-
4李坚,刘琦,关晓东,谢玉妍,陈红涛,张百萌.利用右肾动脉行入肝门静脉动脉化加门腔分流术的实验研究[J].中华普通外科杂志,2010,25(3):227-230. 被引量：13
-
5李坚,关晓东,刘琦,谢玉妍,蔡潮农,张百萌.入肝门静脉动脉化加门腔分流术对大鼠肝脏再生的影响[J].中山大学学报（医学科学版）,2010,31(4):508-512. 被引量：9
-
6CHEN Yong-liang,CHEN Wen-bin,WAN Yun-yan,LI Wen-gang,HUANG Zhi-qiang,WU Xiao-tong,YANG Jie,YANG Li.Effects of partial portal vein arterialization on liver regeneration after hepatectomy in minipigs with obstructive jaundice[J].Chinese Medical Journal,2012(13):2302-2305. 被引量：6
-
7蔡潮农,李坚,李培平,关晓东,周文英,陈红涛,谢玉研,张百萌.门静脉动脉化加门腔分流对肝硬化大鼠肝功能的影响[J].中山大学学报（医学科学版）,2012,33(4):476-480. 被引量：8
-
8蔡潮农,李坚,李培平,关晓东,周文英,陈红涛,谢玉研,张百萌.门静脉动脉化加门腔分流对肝硬化大鼠肝储备功能的影响[J].中华普通外科学文献（电子版）,2012,6(5):23-26. 被引量：6
-
1吴兵.食管胃静脉曲张破裂出血的诊治规范[J].苏州医学,2009,32(1):6-9.
-
2任朝英,贾漪涛,赵武杰,李亚星,王斌.伽玛刀治疗恶性肿瘤所致上腔静脉综合征31例临床观察[J].临床荟萃,2013,28(12):1382-1382. 被引量：1
-
3周静,斯光晏,陈晓梅.彩色多普勒对原发性肝癌介入治疗后的疗效评价[J].泸州医学院学报,2002,25(4):315-316. 被引量：2
-
4李明海.肺血栓栓塞症的诊断和治疗进展[J].哈尔滨医药,2009,29(6):85-87.
-
5郑惠方.子宫肌瘤——女性第—瘤[J].女性天地,2005(12):50-51.
-
6赵洪生.以淋巴结转移为首发症状的隐匿性甲状腺癌8例分析[J].中国冶金工业医学杂志,2009,26(3):358-358.
-
7张德莲,常桂娟,骆秦,左君丽,李南方.嗜铬细胞瘤与原发性高血压间的血尿电解质水平的差异[J].新疆医学,2006,36(2):21-22.
-
8刘颖,周清华,张尚福,刘伦旭,李俸媛,薛洋,车国卫.内皮抑素在非小细胞肺癌中的表达及其与肺癌临床病理生理特征的关系[J].中国肺癌杂志,2002,5(6):447-450. 被引量：15
-
9闫辉.综合疗法治疗肺癌并发上腔静脉综合征47例分析[J].人民军医,2013,56(3):335-336.
-
10胸壁视诊[J].中国社区医师,2013(22):41-41.
